Kardianova – Revolutionizing cardiac risk studies

Revolutionizing precision heart protection in cancer

KardiaNova is an innovative biotech company addressing the unmet global burden of cardiotoxicity in breast cancer patients.

Why this matters

+2.3mio new cases of breast cancer every year globally

+685k yearly deaths
by breast cancer

1/8 women get
breast cancer

1/3 women who survive breast cancer eventually die of heart disease

Our solution

KardiaNova’s proprietary organoid technology is uniquely ready to provide a highly accurate & scalable platform for studying cardiotoxicity risk using human cardiac tissues containing patient-derived cells. This innovative approach offers several advantages:

How it works

KardiaNova’s goal is to achieve proof-of-concept (POC) for our organoid technology. After success in breast cancer our protected platform methodology can be applied to other common cancers such as: NSCLC, CRC, lung, melanoma, ovarian and prostatic cancers.

Key team members

Prof Andrew JS Coats

CEO & scientific director of HRI (Sydney)

Prof Andrew JS Coats, DM, DSc, MBA, AO is co-founder of PsiOxus Therapeutics, Actimed Therapeutics and BioVentrix.

Work experience

Hospital leader and biotechnology entrepreneur

Biotechnology, Health, and Education

Board Member experience in: Finance, External, Audit, NED, CEO and Chairman

Scientific activity

Chairman or Committee member of multiple Cardiovascular and Cancer Cachexia Clinical Trials

Editor-in-Chief of the International Journal of Cardiology for 20 years

President Heart Failure Association of ESC (2020-2022)

Ranked top academic cardiologist in the Asia-Pacific region

Awards & achievements

More than 20 patents awarded (with more than $10M in IP licence fees)

Has raised a total of more than $500M in donations and equity investment

President Heart Failure Association of ESC (2020-2022)

Helped secure Biotech sales for USD10M and licensing deals of USD123.5M and USD$936M (including USD$50 million upfront)

Helped secure over 100M USD in investment rounds in board roles in Biotech companies

Awarded Officer of the Order of Australia

Oxford

Cambridge

Imperial college

University of Sydney

London Business School

H-Index 164

1,000+ publications

160,000+ citations

David Haine

CBO & Board Member at One LiiF (Brussels)

Work experience

International Business Leader and Entrepreneur with a solid track record & focus on Business, Finance & FinTech, Technology, Healthcare and Data & AI.

+15 years corporate experience & international leadership roles for companies like GE Capital, Xeikon, CBRE, Joyn

+15 years experience in (digital) healthcare & technology Patient1Record4Belgium, Heartkinetics, BeWell

Awards & Achievements

Raised +EUR 250M in equity investment & funding

Received the Pinnacle Award from Jeff Immelt (CEO GE) for the international TEF project (alternative funding project during the banking crisis)

Start-up of the year award with Interoffices

Hub

Oxford

Dr Carmine Gentile

Senior Lecturer School of Biomedical Engineering (Sydney)

Work experience

Internationally recognized expert in the field of 3D bioprinting and stem cell technologies

Leader of the Cardiovascular Regeneration Group working on 3D bioprinting and stem cell technologies both at the Heart Research Institute and UTS

Awards & Achievements

Supported by several awards and grants, Dr Gentile has worked at the Heart Research Institute, the University of Sydney and now at UTS, within a multidisciplinary team with scientists, industry partners and clinicians to quickly translate his findings from bench to bedside (Since 2013 )

Scientific experience

Internationally recognized for his studies in 3D bioprinting and stem cell technologies and his more recent studies focus on novel molecular and cellular approaches to treat cardiovascular disease, including myocardial infarction and heart failure

Visiting Research Fellow at Harvard Medical School, where he worked towards novel in vitro models using mini-hearts to study human heart physiology

Chair of the Australian Bioprinting Workshop, the TERMIS Global Editorial Committee, as well as other several Editorial roles accross Journals and Societies

University of Pisa, Medical University of South Carolina, Charleston, SC, USA

H-Index 20

80+ publications

1,600+ citations

Prof Stéphane Carlier, MD, PhD

Chief of Cardiology, CHU Helora – site Kennedy – Mons Professor of Cardiology, University of Mons (UMons), Belgium

Work experience

Bioengineering, Health, Medical Affairs and Education

Full Professor of Cardiology, UMons (B)

Assistant Professor, Clinical Medicine & Bioengineering, Columbia University (NY)

Director, Intravascular Imaging & Physiology, Cardiovascular Research Foundation (NY)

Consultant for BioTech and Medical Devices companies

Director of Medical Affairs EMEA (Cordis)

Awards & Achievements

Laureate of an IBM research and travel grant @ IBM Watson Research Center (NY)

Prize of the “Ordre des Ingénieurs du Québec“

Laureate of the Belgian Society of Cardiology, the Vésale Foundation and the Bekales Foundation

Laureate of the Belgian American Educational Foundation

Research fellowship of the European Society of Cardiology

Bryan Emmerson Visiting Professor, University of Queensland, Brisbane (AUS)

Scientific experience

Expert in complex percutaneous coronary interventions

International proctoring for intravascular imaging

Atherosclerosis and Cardio-Oncology, from bench to bedside

Artificial Intelligence, for the prediction of Atrial Fibrillation

Development of new clinical tools to assess vascular health (Interreg European grant)